The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)

Not Applicable

Recruiting

• Conditions: Multiparametric MRI; Lesion PI-RADS 3

• Registration Number: NCT06867588
• Lead Sponsor: Jules Bordet Institute

Brief Summary

Prostate Specific Membrane Antigen (PSMA) positron emission tomography/computed tomography (PET/CT), an imaging modality focusing on a protein overexpressed by prostate cancer cells, has revolutionised the staging of both newly diagnosed and biochemically recurrent prostate cancer with better performance when compared to conventional imaging. Indeed, several studies have shown that PSMA PET/CT outperformed choline PET/CT with better detection rate of metastatic disease, particularly in the setting of disease recurrence after therapy even at (very) low PSA level. Moreover, the proPSMA trial reported that PSMA PET/CT had 27% greater accuracy than that of CT and bone scanning when staging patients with high-risk localised prostate cancer. More recently, availability of integrated PET/MRI scanners offers the opportunity for higher accuracy imaging and promising diagnostic studies. It also offers enhanced spatial integration that resulting in better contouring and targeting of prostate lesions.

In the light of current issues, the next question is whether PSMA PET imaging could add to the detection of prostate cancer. Several retrospective case-report studies reported promising results regarding the improved diagnostic accuracy of prostatic PSMA PET/CT . Recently, in the PRIMARY trial, 291 men received successively MRI, PSMA PET/CT and systematic ± MRI-targeted biopsies. Despite similar PPV between imaging methods, the main advantage of PSMA was in men with equivocal MRI. Indeed, they found that 90% of csPCa was identified by PSMA PET/CT in this subgroup and paved the way for further investigation. This finding was confirmed in the most recent systematic review and meta-analysis.

The aim of this prospective study is to evaluate the added-value of PSMA PET in detecting prostate cancer in patients who are candidates for biopsy with equivocal MRI.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-10-17
• Status Verified: 2025-02
• Study First Submitted: 2025-02-25
• Study First Submitted QC: 2025-03-04
• Study First Posted: 2025-03-25
• Last Update Submitted: 2025-03-26
• Last Update Posted: 2025-03-31
• Primary Completion: 2026-10
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 68

Inclusion Criteria

Subjects must meet the following criteria for inclusion in the study:

• Men ≥ 18 years of age
• Multiparametric MRI within the previous 6 months
• At least one lesion PI-RADS 3
• Able to provide written informed consent

Exclusion Criteria

Eligible subjects must not meet any of the exclusion criteria listed below:

• Previous prostate cancer diagnostic on MRI-targeted biopsy
• At least one lesion PI-RADS 4-5
• Negative MRI (PI-RADS 1-2)
• Previous treatment for prostate cancer 11
• Contraindication to PSMA PET and/or MRI and/or prostate biopsy
• Low quality of MRI defined by a PI-QUAL score of 1 or 2
• Any medical condition that may interfere with the study procedures.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Percentage of patients with clinically significant prostate cancer detected by PSMA PET-targeted biopsy	Baseline

Trial Locations

Locations (1)

Institut Jules Bordet; 🇧🇪 Brussels, Belgium